Your browser is no longer supported. Please, upgrade your browser.
Revance Therapeutics, Inc.
Index- P/E- EPS (ttm)-4.72 Insider Own1.80% Shs Outstand67.46M Perf Week-4.88%
Market Cap1.95B Forward P/E- EPS next Y-3.67 Insider Trans-8.23% Shs Float65.68M Perf Month2.04%
Income-303.40M PEG- EPS next Q-1.15 Inst Own88.90% Short Float5.52% Perf Quarter-13.77%
Sales47.10M P/S41.48 EPS this Y-32.60% Inst Trans6.07% Short Ratio9.06 Perf Half Y-4.71%
Book/sh2.76 P/B9.60 EPS next Y23.70% ROA-44.10% Target Price38.80 Perf Year-22.77%
Cash/sh4.56 P/C5.81 EPS next 5Y11.60% ROE-103.10% 52W Range22.89 - 34.62 Perf YTD-6.53%
Dividend- P/FCF- EPS past 5Y-10.00% ROI-48.80% 52W High-23.48% Beta1.25
Dividend %- Quick Ratio6.00 Sales past 5Y119.60% Gross Margin69.40% 52W Low15.73% ATR1.02
Employees470 Current Ratio6.10 Sales Q/Q22829.30% Oper. Margin- RSI (14)42.68 Volatility4.43% 3.55%
OptionableYes Debt/Eq1.50 EPS Q/Q4.20% Profit Margin- Rel Volume0.83 Prev Close26.52
ShortableYes LT Debt/Eq1.50 EarningsAug 05 AMC Payout- Avg Volume399.90K Price26.49
Recom1.80 SMA20-1.79% SMA50-6.87% SMA200-5.73% Volume332,217 Change-0.11%
Oct-15-20Reiterated Needham Buy $36 → $42
Aug-11-20Resumed Mizuho Buy $32
Mar-23-20Downgrade Goldman Buy → Neutral $32 → $15
Dec-02-19Initiated Goldman Buy
Oct-30-19Upgrade Wells Fargo Market Perform → Outperform $20
Jun-11-19Initiated Barclays Overweight $28
Feb-15-19Initiated Wells Fargo Market Perform
Feb-14-19Initiated H.C. Wainwright Buy $25
Jan-29-19Initiated Stifel Buy $50
Nov-16-18Upgrade Guggenheim Neutral → Buy
Sep-17-18Downgrade JMP Securities Mkt Outperform → Mkt Perform
Apr-20-18Reiterated Mizuho Buy $54 → $48
Mar-27-18Initiated Needham Buy $42
Mar-05-18Initiated Goldman Buy $60
Jan-09-18Downgrade Guggenheim Buy → Neutral
Dec-06-17Reiterated Mizuho Buy $37 → $54
Dec-06-17Initiated Guggenheim Buy $42
Nov-27-17Initiated Barclays Overweight $31
Nov-17-17Initiated Mizuho Buy $37
Aug-22-17Initiated JMP Securities Mkt Outperform $34
Sep-16-21 08:00AM  
Sep-13-21 11:46AM  
Sep-10-21 08:00AM  
Sep-02-21 08:00AM  
Sep-01-21 08:00AM  
Aug-05-21 07:05PM  
Jul-29-21 03:05PM  
Jul-12-21 09:35AM  
Jun-03-21 05:39AM  
May-26-21 04:05PM  
May-11-21 08:17AM  
May-10-21 06:05PM  
May-03-21 08:00AM  
Apr-29-21 12:34PM  
Apr-27-21 04:05PM  
Apr-23-21 08:00AM  
Apr-06-21 04:05PM  
Apr-01-21 08:00AM  
Mar-22-21 04:05PM  
Mar-12-21 04:06AM  
Feb-24-21 04:05PM  
Feb-23-21 04:05PM  
Feb-22-21 05:25PM  
Feb-19-21 10:40AM  
Feb-12-21 08:00AM  
Jan-25-21 08:00AM  
Jan-22-21 08:00AM  
Jan-19-21 04:05PM  
Jan-11-21 07:45AM  
Jan-07-21 04:05PM  
Dec-23-20 01:30PM  
Dec-22-20 08:00AM  
Dec-21-20 04:05PM  
Dec-17-20 08:05AM  
Dec-16-20 08:30AM  
Dec-14-20 10:47AM  
Nov-27-20 01:31PM  
Nov-25-20 08:30AM  
Nov-24-20 04:05PM  
Nov-20-20 04:05PM  
Nov-11-20 08:08AM  
Nov-10-20 04:05PM  
Nov-09-20 05:16PM  
Nov-06-20 09:00AM  
Nov-03-20 04:05PM  
Nov-02-20 04:05PM  
Oct-23-20 04:05PM  
Oct-14-20 08:00AM  
Oct-06-20 08:00AM  
Oct-05-20 10:15AM  
Sep-23-20 04:05PM  
Sep-08-20 04:05PM  
Sep-02-20 08:00AM  
Aug-28-20 11:29AM  
Aug-25-20 08:00AM  
Aug-11-20 08:30AM  
Aug-06-20 04:05PM  
Jul-30-20 04:05PM  
Jul-24-20 09:46AM  
Jul-23-20 06:20PM  
Jul-05-20 03:28PM  
Jun-30-20 04:05PM  
Jun-26-20 09:57AM  
Jun-18-20 12:27PM  
Jun-09-20 08:10PM  
Jun-04-20 04:05PM  
Jun-02-20 04:05PM  
Jun-01-20 08:30AM  
May-20-20 08:12AM  
May-19-20 08:01AM  
May-09-20 10:01PM  
May-07-20 04:05PM  
May-01-20 08:30AM  
Apr-30-20 04:05PM  
Apr-27-20 09:16AM  
Apr-21-20 08:05AM  
Apr-09-20 08:55AM  
Apr-07-20 04:05PM  
Mar-26-20 04:05PM  
Mar-25-20 08:36AM  
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection (DAXI), which has completed phase III clinical trials for the treatment of glabellar (frown) lines and cervical dystonia; is in phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing DAXI in preclinical trial for the treatment of migraine, as well as a topical program for various indications; and OnabotulinumtoxinA, a biosimilar to BOTOX. The company has a collaboration and license agreement with Viatris Inc. for the development and regulatory approval of a biosimilar to BOTOX. The company was formerly known as Essentia Biosystems, Inc. and changed its name to Revance Therapeutics, Inc. in April 2005. Revance Therapeutics, Inc. was incorporated in 1999 and is headquartered in Newark, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rankin AubreyPresident, Innovation & TechAug 16Sale26.349,364246,65965,463Aug 17 06:20 PM
Rankin AubreyPresident, Innovation & TechJul 28Sale30.0654,3321,632,960154,302Jul 30 08:57 PM
Rankin AubreyPresident, Innovation & TechJul 26Sale29.7255,3821,645,953355,943Jul 28 09:48 PM
Rankin AubreyPresident, Innovation & TechApr 05Sale28.28257411,325Apr 06 07:41 PM
Rankin AubreyPresident, Innovation & TechMar 04Sale25.4333,119842,216411,327Mar 05 08:10 PM
Rankin AubreyPresident, Innovation & TechFeb 01Sale25.9533,119859,438444,446Feb 03 08:13 PM
Rankin AubreyPresident, Innovation & TechDec 30Sale27.8233,119921,212477,565Jan 04 08:01 PM
Rankin AubreyPresident, Innovation & TechNov 30Sale23.8533,119789,888510,684Dec 02 08:55 PM
Rankin AubreyPresident, Innovation & TechOct 29Sale26.1533,119865,949543,803Oct 30 08:24 PM
Rankin AubreyPresident, Innovation & TechSep 28Sale26.1833,119867,055576,922Sep 30 09:21 PM